Comparative Pharmacology
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE versus INDERIDE LA 120 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE versus INDERIDE LA 120 50.
ESMOLOL HYDROCHLORIDE vs INDERIDE LA 120/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min; titrate by 25-50 mcg/kg/min every 5-10 minutes up to 200 mcg/kg/min.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
None Documented
None Documented
Terminal elimination half-life: approximately 9 minutes in adults (range 4–13 min); in patients with hepatic impairment: unchanged; in severe renal impairment: prolonged to 12–20 min due to metabolite accumulation. Clinically, rapid offset (within 20–30 min) allows for titration.
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Rapid metabolism by red blood cell esterases to inactive acid metabolite (ASL-8123) and methanol; <2% excreted unchanged in urine; primarily renal elimination of metabolites.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Category A/B
Category C
Beta-Blocker
Beta-Blocker/Diuretic Combination